Table 3.

Univariate and multivariate analyses of overall and progression-free survival.

Variable	No. event /total	PFS				No. event /total	OS
		Univariate analysis		Multivariate analysis			Univariate analysis		Multivariate analysis
		HR(95% CI)	P value	HR(95% CI)	p value		HR (95% CI)	p value	HR (95% CI)	p value
Age > 60y	17/25	1.47(0.71–3.05)	0.299			13/25	2.83(1.04–7.69)	0.041	2.56(0.91–7.21)	0.074
Deep-brain involvement	20/31	1.11(0.55–2.25)	0.755			13/31	0.90(0.38–2.11)	0.805
ECOG > 3	9/10	1.94(0.89–4.20)	0.095	1.80(0.76–4.29)	0.183	7/10	2.83(1.15–7.00)	0.024	3.14(1.16–8.54)	0.025
Elevated LDH	5/7	1.12(0.53–2.38)	0.764			4/7	1.73(0.58–5.12)	0.323
Multiple focal	18/24	1.84(0.92–3.66)	0.083	1.42(0.63–3.21)	0.399	12/24	1.49(0.64–3.45)	0.353
Cytarabine treatment	8/14	0.97(0.44–2.16)	0.940			6/14	1.09(0.43–2.80)	0.853
WBRT consolidation	5/11	0.35(0.14–0.92)	0.033	0.39(0.12–1.16)	0.088	3/11	0.38(0.11–1.28)	0.118
GCB subtype	3/11	0.24(0.07–0.79)	0.019	0.21(0.06–0.73)	0.014	2/11	0.28(0.07–1.21)	0.089	0.30(0.07–1.31)	0.109
CR at the end of treatment	11/25	0.32(0.15–0.66)	0.002	0.35(0.16–0.76)	0.009	6/25	0.26(0.11–0.74)	0.006	0.20(0.07–0.55)	0.002
≤ 19 months	11/25	0.22(0.10–0.50)	0.000	0.32(0.14–0.76)	0.01	6/25	0.18(0.04–0.83)	0.028	0.17(0.04–0.80)	0.025
> 19 months	3/12	0.74(0.08–7.25)	0.797	1.23(0.11–13.7)	0.86	2/20	0.36(0.10–1.29)	0.12	0.17(0.03–0.93)	0.041

Notes CI, confidential interval; CR, complete remission; HR, hazard ratio; ECOG, Eastern Cooperative Oncology Group; GCB, germinal center B-cell-like; LDH, lactate dehydrogenase; OR, overall remission; OS, overall survival; PFS, progression-free survival.